Score Overview
PeriodNet IncomeRevenueScoreGrowthTrendConsistencyGrowthTrendConsistency
5 Years
8.5
117.86%
Every year
—
16x
Every year
—
5 Years
Score8.5
Net Growth117.86%
Net TrendEvery year
Net Income Consistency—
Rev Growth16x
Rev TrendEvery year
Revenue Consistency—
Apellis Pharmaceuticals Inc fundamental performance
Between 2020 and 2025, revenue grew from $ 250M to $ 1.00B and net income went from -$ 344M to $ 22M. Revenue increased in every one of those 5 years; net income in every one.
Apellis Pharmaceuticals Inc currently holds a 5-year HDB Score of 8.5 out of 10. How the HDB Score is calculated.
Net Income x Stock Price
Historical Returns
| Period | Price | Return |
|---|---|---|
Last Price2026-08-12 | $ 3.42 | — |
1 Year2025-08-13 | $ 26.58 | -87.13% |
5 Years2021-08-13 | $ 57.46 | -94.05% |
All Time2017-11-09 | $ 14.03 | -75.61% |
| Period | Last Price2026-08-12 | 1 Year2025-08-13 | 5 Years2021-08-13 | All Time2017-11-09 |
|---|---|---|---|---|
| Price | $ 3.42 | $ 26.58 | $ 57.46 | $ 14.03 |
| Return | — | -87.13% | -94.05% | -75.61% |
Prices are split & dividend adjusted. All values are reported in USD.
Fundamental Data
| Year | |||
|---|---|---|---|
| 2026 | $ 1.10B | $ 133M | $ 406M |
| 2025 | $ 1.00B | $ 22M | $ 467M |
| 2024 | $ 781M | -$ 197M | $ 416M |
| 2023 | $ 396M | -$ 528M | $ 352M |
| 2022 | $ 75M | -$ 652M | $ 551M |
| 2021 | $ 66M | -$ 746M | $ 701M |
| 2020 | $ 250M | -$ 344M | $ 877M |
| 2019 | $ 0.00 | -$ 304M | $ 351M |
| 2018 | $ 0.00 | -$ 127M | $ 176M |
| IPO2017 | $ 0.00 | -$ 51M | $ 175M |
Explore beyond APLS
You're looking at Apellis Pharmaceuticals Inc. Members apply the same fundamental framework across all 3,859 companies we cover.
- Every HDB Score — 1, 5, 10, 20 and 30 years, plus all-time
- Revenue and Net Income Consistency for every period
- Rank all 3,859 companies by any metric, not just three
- Filter by sector and currency, and page through the whole list
- Track your holdings in a portfolio
$99/year $149 founding price
Unlock Holder Dashboard30-day money-back guarantee.
